stein, you're right that news from Mabcure is overdue.
While we wait for that, check out Arrayit Corp. (ARYC) which is a company that is developing a screening test for Ovarian cancer.
They have announced that their OvaDx test is around 90% sensitivity and 100% specific i.e there are no false positives with this test and it finds 9 out 10 ovarian cancers of all types and stages (I thru IV).
SUNNYVALE, Calif., April 4, 2012 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB: ARYC) and Arrayit Diagnostics, Inc. ("AD") report significant results from a 257 patient research study on its pre-symptomatic ovarian cancer molecular diagnostic test in development, OvaDx®. In this study, OvaDx® recorded sensitivity of 79.7%, correctly identifying patients known to have cancer, and specificity approaching 100%, correctly identifying the healthy controls, patients known not to have cancer.
"We continue to make additional enhancements subsequent to this pilot study that indicate improvements in the sensitivity number approaching 90%. We are working to make this diagnostic test superior to any existing test. Requiring only a finger stick of blood, this will also be the easiest test to administer," says Dr. Mark Schena, President and Chief Scientific Officer of Arrayit Corporation."
Since July of 2009, AD has operated as an independent subsidiary of Arrayit Corporation and holds all the intellectual property, licenses and development agreement assets related to the pre-symptomatic ovarian cancer diagnostic test known as OvaDx®. On December 14th, 2011, Arrayit Corporation announced the spin-off of AD and the distribution of its 78.18% interest in AD as a stock dividend to ARYC shareholders. The record date, dividend distribution date and further details will be announced shortly.
------------------
Check out recent tweets on their twitter feed. ARYC stock is now 0.25 but it's bound to go higher soon.
www.twitter.com/arrayit
